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Abstract
The biomedical research sector in Saudi Arabia has recently received special attention from the government, which
is currently supporting research aimed at improving the understanding and treatment of common diseases
afflicting Saudi Arabian society. To build capacity for research and training, a number of centres of excellence were
established in different areas of the country. Among these, is the Centre of Excellence in Genomic Medicine
Research (CEGMR) at King Abdulaziz University, Jeddah, with its internationally ranked and highly productive team
performing translational research in the area of individualized medicine. Here, we present a panorama of the
recent trends in different areas of biomedical research in Saudi Arabia drawing from our vision of where genomics
will have maximal impact in the Kingdom of Saudi Arabia. We describe advances in a number of research areas
including; congenital malformations, infertility, consanguinity and pre-implantation genetic diagnosis, cancer and
genomic classifications in Saudi Arabia, epigenetic explanations of idiopathic disease, and pharmacogenomics and
personalized medicine. We conclude that CEGMR will continue to play a pivotal role in advances in the field of
genomics and research in this area is facing a number of challenges including generating high quality control data
from Saudi population and policies for using these data need to comply with the international set up.
Introduction
Leadership of the Kingdom of Saudi Arabia, is more
conscious than ever of the necessity of establishing dedi-
cated and long-term strategies that focus on the preven-
tion of the effects of severe genetic disorders (most
often due to consanguinity) and the impact of environ-
mental changes (e.g., Dietary changes, toxins) on the
general health of the Saudi society. As outlined in
Figure 1, health policy planners and biomedical research
scientists have conducted landscape surveys of the chal-
lenges facing the Saudi population, and formulated stra-
tegic objectives of how to move the health care research
agenda forward with defined outcomes. Many of the
decisions in investment in biomedical solutions for
looming medical challenges are being grounded in
establishing high-technology genomics and informatics-
based centres that exploit the unique clinical and
human resources available in the Middle Eastern coun-
tries, and in particular Saudi Arabia. International exper-
tise is also being brought in through forward looking
academic consultancies with universities and through
new training initiatives.
In order to apply 21st century solutions in biomedical
health research, at least three foundational genomic
research initiatives are under way in the Gulf Coopera-
tion Council (GCC), which include Kingdom of Saudi
Arabia, Qatar, Oman, Bahrain, Kuwait and United Arab
Emirates. These initiatives include, the catalogue of
transmission genetics in Arabs (CTGA) [1] hosted by
the Centre for Arab Genomic Studies in the United
Arab Emirates, the Qatar Biobank Initiative [2] and the
Saudi human genome program (SHGP) [3].
Established in 2003, the main purpose of the CTGA is
to increase public and academic awareness for early
diagnosis of genetic diseases in the Pan Arab population
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and to translate scientific knowledge into individualized
medical treatment and management programs. As of Janu-
ary 2014, the CTGA online database curates over 1,000
disease phenotypes with a focus on the epidemiology in
the Arab world, and it also maintains a record of nearly
250 associated disease loci. Many of the disease pheno-
types studied are either more frequent (such as G6PD
deficiency) or are regionally endemic, restricted to certain
Figure 1 Challenges, objectives and expected outcomes of biomedical research in Saudi Arabia.
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tribal communities or even unique to consanguine
families. Consanguinity, which is a main feature of the tra-
ditional Arabic culture (see below), leads to an increase of
homozygosity for autosomal recessive genetic diseases
which, from the perspective of research, can serve as an
important repository for phenotype-genotype association
studies [4]. The Qatar BioBank was initiated in 2010 aim-
ing to take biosamples from Qatari population into reposi-
tory to investigate diseases common to the domestic
population [2]. Its ambitious goal is to serve as a driver
for biomedical research inside and outside of Qatar. The
SHGP intends to sequence the exomes and/or genomes of
100,000 Saudis within a period of five years taking advan-
tage of the feasibility of next generation sequencing (NGS)
[3]. In one of the large investments, NGS utilizing the Ion
Proton technology (LifeTechnologies) has been allocated
to the core facility of the SHGP in the capital Riyadh in
addition to 15 planned satellite facilities across the King-
dom covering a substantial part of the 30 million nation’s
populated areas. The satellites are established as collabor-
ating institutions with self-adopted timelines and projects,
which are led by on-site researchers independently from
the SHGP headquarter.
Using the new genomic data, the SHGP is aiming to
investigate a number of diseases, which are common or
endemic in the country and have a strong genetic com-
ponent such as diabetes, deafness, cardiovascular disease,
neurodegeneration, cancer and inherited and Mendelian
disorders (discussed below). Translational research
aspects of this project include genetic counselling and in
some instances further genetic testing of families where
the underlying genetic mutations have been identified.
For example, a number of genetic counselling services for
inherited disorders like the pre-marital screening and
genetic counselling program in Saudi Arabia for hemo-
globinopathies and viral infections have been implemen-
ted [5]. Developing applications in pharmacogenomics
research and personalized medicine are prospective
objectives that may also arise from the SHGP. In addi-
tion, the aggregate genetic information offers the oppor-
tunity to perform genome wide association studies
(GWAS) in a new dimensional scale. Such studies may
shed light upon a number of polymorphic traits that are
associated with certain diseases and are suspected to add
to their penetrance which may gain special importance
for endemic conditions like body mass index and obesity
[6], or for acute diseases like cancer [7].
Our review is divided into five themes that we believe
are most relevant for genomic technologies to have
impact in Saudi Arabia. We ordered the themes based
on our interpretation of the challenges unique to Saudi
Arabia and the Middle East (Fig. 1). We believe the
investment in research will have significant impact on
our own health care systems and the lessons learned
will also have an impact in other regions of the world, in
particular as population migration expands and genetics
becomes fully integrated into medical management for
individuals and their family members [8]. Our vantage
point is from working within the Centre of Excellence in
Genomic Medicine Research (CEGMR), King Abdulaziz
University (KAU), Jeddah, Kingdom of Saudi Arabia
(KSA). This dynamic organization is aiming to develop
and apply the best practices in genomic medicine driven
by world-class research programs (Fig. 2) to further the
health of citizens of Saudi Arabia and the world.
I. Congenital malformations in Saudi Arabia
Congenital malformations are identified as physical irrever-
sible alterations induced during embryo formation that can
be grouped into five categories: (1) single-gene anomalies,
(2) chromosomal abnormalities, (3) maternal illness condi-
tions during early pregnancy, (4) environmental and
genetic inducers (e.g., teratogens), and (5) unknown causes,
which account for ~50% of congenital malformations [9].
In Saudi Arabia, a number of studies were carried out to
screen for congenital abnormalities in different regions of
the kingdom (Fig. 3). In the Western province of Saudi
Arabia, a high prevalence of major congenital abnormal-
ities including cardiovascular, musculoskeletal, urinary and
central nervous system (CNS) was reported [10]. Interest-
ingly, this study showed that at least 38% of the parents of
babies with congenital malformations were consangui-
neous. More supporting evidence from large multicentre
studies conducted across Riyadh and the Eastern region
revealed that first cousin marriage have a direct link with a
number of congenital heart defects (CHD) [11-14]. Severe
CHD were also reported in large studies in Al-Qassim
(central region) with authors attributing the severity to the
high rate of consanguinity [15,16]. These findings are not
surprising since Saudi Arabia has the highest consangui-
nity among all middle eastern countries [17]. Based on
Saudi Arabian regional distribution, South-Western and
Northern provinces have the highest prevalence of CHD
(Fig. 3)[18]. In Najran in South province, a significant high
prevalence of hypothyroidism and hyperthyroidism asso-
ciated with CHD were reported and attributed to high rate
of consanguinity [19-21]. In Asir region in the South pro-
vince, a high prevalence of a number of congenital malfor-
mations was detected in newly born babies and found to
be linked to high consanguinity. Among these are gastro-
intestinal tract anomalies [22], CNS defects [23,24] and
cardiovascular system defects [25]. All previous studies
used hospital database analysis, however, the first commu-
nity based study to measure the prevalence of CHD was
carried out by Alqurashi, et al., 2007 [26]. This study
showed that the central region had the highest CHD pre-
valence of 27 per 10,000 and the north-western was the
least affected region with prevalence of 9 per 10 000 [26].
Abu-Elmagd et al. BMC Medical Genomics 2015, 8(Suppl 1):S3
http://www.biomedcentral.com/1755-8794/8/S1/S3
Page 3 of 17
Figure 2 Centre of Excellence in Genomic Medicine Research (CEGMR) Multi-disciplinary platforms in biomedical research.
Figure 3 Regional prevalence of cardiac heart defects (CDH) in the Kingdom of Saudi Arabia.
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A wide range of the CNS malformations including neural
tube defects have been detected in different regions of
Saudi Arabia with consanguinity appearing to be a major
risk factor [23,24,27,28]. The mountainous geography of
Saudi Arabia may also contribute to the high rate of con-
genital malformations since high altitude has been
reported in other regions worldwide as a cause of congeni-
tal anomalies [29-31]. In Al-Taif city, known as a very
high-altitude area, an increase in cardiovascular, urogen-
ital, musculoskeletal, gastrointestinal, and cleft palate
anomalies in addition to chromosomal abnormalities were
reported [32].
Due to strong economic stability, obesity in Gulf
countries in general and in Saudi Arabia and Kuwait in
particular has become a high risk factor and a serious
problem that reflects negatively on the these societies
[6]. According to the Saudi Arabian national nutrition
survey issued in 2007, the prevalence of obesity among
women is 23.6% compared to 14.2% in men [33]. It has
been reported that a mother’s body mass index of more
than 30 is a predictor of a number of congenital malfor-
mations including cardiac, nervous system, facial and
genitourinary tract defects [34]. Environmental factors
and metabolic disorders are believed to induce congeni-
tal infections with toxoplasmosis, and cytomegalovirus
that in turn result in inducing a number of congenital
malformations including; microcephaly, seizures and
intracranial calcification [35,36].
Different genomic research approaches to elucidate
the causes of congenital anomalies in Saudi Arabia have
recently begun to gain more attention. For example, a
multi-level technology approach was used to unravel the
molecular network that lead to cryptorchidism [37].
Comparative genomic hybridization (CGH) was also
used to analyse chromosome microdeletions that caused
upper limbs disabilities [38], and exome sequencing led
to the identification of the ADAMTS18 gene to be
involved in eye development [29].
Despite a recommendation to launch a national
screening program for congenital anomalies in 1997
[20], there remains a real need for a primary national
prevention program. We believe this type of program
should be congruent with an awareness program of the
genetic and epigenetic causes of the birth defects in
Saudi Arabia. There is support for the implementation
of an extensive pre-marital and pre-implantation screen-
ing program, in addition to establishing a national data-
base for congenital anomalies, and by offering genetic
counselling when birth defects occur [39,40]. Recently,
King Faisal Specialist Hospital & Research Centre
(KFSH & RC) in Riyadh launched a technical database
core facility that aims to maintain database registries of
a number of diseases and congenital defects in order to
facilitate clinical and research domains in Saudi Arabia
(http://rc.kfshrc.edu.sa/besc/sections/tdbcf/OurProjects.
html). Among these registries are; new-born screening
and biochemical genetics (http://nlnbs.kfshrc.edu.sa),
cleft lip/palate and craniofacial anomalies (http://rc.
kfshrc.edu.sa/bssc/clcpr_new/buttons/New_Site.htm),
congenital heart defects (http://rc.kfshrc.edu.sa/
chd_program/) and neural tube defects (http://rc.kfshrc.
edu.sa/ntd/). Establishing similar regional initiatives con-
nected to a central database facility would reveal the
most accurate data on congenital malformations in Saudi
Arabia.
At CEGMR, a number of research initiatives are
already in place to screen and investigate the causes of
congenital malformations in Saudi Arabia. Among these
initiatives are KACST’s recently funded projects to apply
microarray based CGH approach to unravel genome
defects in the congenital heart diseases and another to
screen and diagnose the developmental delay as well as
other congenital malformations. In addition, CEGMR
established a collaboration with the Environmental
Sciences Department at KAU to analyse changes in gene
expression profiling using array CGH, RNA-Seq and
whole exome sequencing during early embryonic devel-
opment that could be induced by air particulate pollu-
tion and pesticides.
II. Infertility and pre-implantation genetic diagnosis (PGD)
Infertility is a condition manifested by the biological inca-
pacity of a couple to achieve a clinical pregnancy after at
least one year of regular unprotected sexual intercourse
[41]. The prevalence of this disease continues to rise and
affects about 1 out of 6 couples in Saudi Arabia and
worldwide [42,43]. Such infertility rates vary largely
among countries and patient age [44]. The most common
factors that could explain this severe decline in fertility
are reproductive aging through the postponement of
marriages, lifestyle, nutrition, the quality of health care
services, and decrease in the child-seeking behaviour
[45-47]. These factors are mainly due to the maternal age
and to a lesser extent the paternal factors that could cor-
relate with increased rates of gametes’ chromosome cohe-
sion and therefore higher aneuploidy and chromosomal
abnormalities in blastocysts [48-50].
There is an increase in the number of couples seeking
infertility treatment services in assisted reproductive
technologies (ART) clinics to help them to procreate.
Despite valuable ART advantages, a remaining challenge
is to increase qualitatively and quantitatively the in vitro
fertilization (IVF) outcomes and reduce health care costs
for both the mother and the offspring [51,52]. The
gametes’ (spermatozoa and oocyte) quality has been
recognized as the major limiting step and is therefore the
target of numerous studies to improve their selection
procedure [53-56], in order to make the elective single
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embryo transfer (eSET) procedure more effective [57,58].
Chromosomal and some genetic mutations have been
reported to underlie many of the challenges for obtaining
successful embryo implantation and subsequent delivery
of healthy babies [59-61].
In addition to the infertility challenges, Saudi society
in particular is characterized as mentioned above by an
extremely high-level of consanguinity. In fact, large pro-
portions of marriages are still driven by ethnic or tribal
considerations. The rate of consanguineous marriages is
about 58% amongst them 60% were between first-degree
cousins [12,17], which represents one of the highest in
the Middle East and worldwide. In addition to the
increase of the frequency of inherited recessive disor-
ders, these consanguineous marriages have direct effects
on some reproductive health parameters such as inferti-
lity rates, recurrent abortions, congenital disorders and
neonatal death (Table 1) [4]. It should be highlighted
that these genetic and chromosomal disorders’ rates are
variable among regions inside Saudi Arabia. Addition-
ally, these rates are exceptionally high in Saudi Arabia
and Middle East in general compared to other regions
in the world due to the burden of consanguinity and
population inbreeding.
Given the challenges of high rates of consanguinity
and disease in the Middle East and in Saudi Arabia, the
Saudi ministry of health (MOH) decided in 2004 to
make the premarital testing compulsory [5,62]. Such
premarital examination includes mainly the basic blood
tests, the hemoglobinopathies screening (Thalassemia &
Sickle Cell Anaemia) and virology assays (Hepatitis B
and C; AIDS). Despite these important measurements,
PGD is still restricted to only few IVF clinics and it is
the opinion of the authors that the level of awareness
about infertility problems and genetic diseases needs to
be given more attention especially in regions with high
consanguinity as well as in rural and tribal areas. Invest-
ment in training and staffing in genetic counselling will
also then be required.
The CEGMR aims to play a leading role in PGD by
building translational research capacity. CEGMR is cur-
rently working in collaboration with KACST Centre of
Innovation for Personalized Medicine (CIPM), Jeddah at
KAU; the latter is being involved in delivering service
through PGD screening for the larger Saudi population.
CEGMR is currently developing new infertility screening
methods using a specific panel of biomarkers with the pri-
mary aim being to reduce the comparatively high recur-
rence of abortions. For examples, new advances in
technology have allowed the transfer of two embryos to
the eSET preventing multiple pregnancies, which can dis-
advantage both the mother and the baby [63]. Similarly, a
new project was recently initiated to establish an advanced
premarital screening (APS) using state-of-the-art
approaches with higher coverage (number of diseases) and
accuracy. Once validated, such APS package will be pre-
sented to the MOH for consideration as an improvement
of the existing test using advanced high throughput
technologies.
Together, fertility and PGD screening programs as well
as the APS package are excellent tools that are on line
with the latest advances in the reproductive and develop-
mental medicine field worldwide and are expected to sig-
nificantly enhance the efficiency of both infertility
diagnosis and treatment [64-66]. They will also facilitate
detection and prevention of the transfer of most of the
inherited disorders to the upcoming generations.
III. Cancer and genomic classifications in Saudi Arabia
All six GCC countries curate national cancer registries
that provide statistics measures to the Gulf centre for can-
cer registration [67-70]. Remarkably, the national cancer
registers of Bahrain, Kuwait, Oman, and Qatar are listed in
a high incidence data quality category as assessed by the
international agency for research on cancer (IARC) [71].
In comparison with USA, cancer data indicates a lower
incidence rate for cancer in the Gulf region (Fig. 4); yet, a
certain deviation of the frequency of the most common
cancer types is observed [72]. For example, thyroid and
liver cancer, as well as leukaemia and non-Hodgkin`s lym-
phoma (NHL) are relatively more common than in the
USA (all races) [68,72]. Thyroid cancer is the second most
frequent cancer in young women in the majority of the
GCC countries [73,74]. Contrarily, prostate cancer is less
frequent in the Gulf region, especially in Saudi Arabia
[75]. In most common cancer types including thyroid and
breast cancer, patients are several years younger at first
diagnosis compared to Western countries [67,72,76,77].
Molecular genetics studies from the Gulf region have
demonstrated that hereditary components like single
nucleotide polymorphisms (SNPs) confer risk for breast
[78] and thyroid cancer [79,80]. More specifically for the
p53 codon, 72 polymorphism showed an association with
early onset of breast cancer in Saudi women [81].
A high prevalence of childhood cancer in relation to
adulthood cancer is observed in the GCC region. This dis-
crepancy is in first instance attributed to the young popu-
lation structure of the region [67,82]. Similar to Western
countries, leukaemia and lymphomas including both
Hodgkin’s lymphoma and NHL are among the most fre-
quent paediatric cancers (Fig. 5). To provide specialized
paediatric cancer care, the King Fahd National Centre for
Children’s Cancer and Research, hosted by KFSH & RC,
was established in 1997 in the Saudi capital Riyadh. The
paediatric clinic, the largest in the region, performs
approximately 70 stem cell transplantations per annum.
One of the research areas of both institutions is focusing
on the molecular genetics of diffuse B-cell lymphomas,
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which are the most common subtype of extranodal NHL
and occur with a comparably high prevalence in the Gulf
region [83-85]. Notable findings include detection of clini-
cally relevant biomarkers such as SKP2, XAIP, FOXM1,
and MET in diffuse large B-cell lymphomas and detection
of molecular mechanisms for NFĸB in activated B-cell
lymphomas [83,86-89]. For acute lymphoblastic leukaemia
(ALL), a Saudi retrospective multicentre study revealed
clinical characteristics similar to those found in developed
countries; however, the authors noticed that standardiza-
tion of patients` care has to be improved [82]. Interest-
ingly, an epidemiological survey in the Detroit area of
USA revealed a higher incidence of leukaemia and bladder
cancer in US-born males of Arab origin compared to non-
Hispanic whites [90] indicating a possible involvement of
inherited susceptibility factors in these malignancy types,
as shown for other diseases like thyroid and breast cancer
[79-81,91]. These findings emphasize the genetic heteroge-
neity of major cancer types, in which NGS may become
the tool for personalized medicine intervention.
IV. Epigenetic explanations of idiopathic disease
A marked feature of cancer in the Kingdom of Saudi
Arabia is the relatively young age of onset. The most
common cancer type in Saudi Arabia is breast cancer
comprising more than 16% of the cases seen at the lar-
gest oncology referral centre in the Kingdom, KFSH &
RC [92]. Most of the affected females are below 50 years
of age [92], which differs from Western countries where
the age of onset is later [93]. Colon cancer is the most
cancer type affecting Saudi males and here too the age of
onset (40-65 years) [92] is less than seen in the west [93].
Table 1 An overview of the main genetic and chromosomal disorder in Saudi Arabia and their relationship with
consanguinity. (++): High correlation; (+): Positive correlation; ND: Not Determined.
Type Disease Disease prevalence* (%) Consanguinity References
Chromosomal Down syndrome 1.8 ND [172]
Congenital Malformations or birth defects 2- 3 ++ [12,13,173]
Polygenic and/or multifactorial Congenital heart disease (CHD) 5.4-10.7 + [15,174,175]
Cystic fibrosis 0.24 ++ [176]
Duchene muscular dystrophy (DMD) 0.025 + [177]
Hereditary Recessive deafness 130 ++ [178-180]
Hereditary blindness & visual impairment 90 ++ [181,182]
Diabetes mellitus 110 to 237 ND [183,184]
Thalassemia 0.5 to 2.6 ++ [185-188]
Monogenic Sickle Cell Disease (SCD) 9 to 14.5 ++ [185,187,189-192]
G6PD deficiency 7.7 to 20 ++ [12,193,194]
*Rates from national and/or regional studies done in Saudi Arabia
Figure 4 Average annual age standardized incidence rates (ASR) of all cancers in males and females from the GCC states in the period 1998-
2007 [68]. For comparison, ASR for cancer in the US in the period 2005-2009 ranged between nearly 290 in Asian American and Pacific Islander
women and approximately 620 in African American men [91].
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The reason for such age discrepancy is not entirely
known. However, factors such as the early age of
menarche (<12 years) and the use of exogenous proges-
terone and oestrogens could be suspected in the case of
breast cancer [94]. The relatively young age of onset in
this population could be explained by the interplay
between common genetic susceptibility background sub-
stantiated by increased consanguinity and epigenetic
aberrations. These factors are thought to be caused by
shifts in life style being experienced in Saudi Arabia and
in the Middle East in general in the past few decades.
Similar life-style shifts are also seen in emerging econo-
mies such as India. Similar to Saudi Arabia, there is an
increasing number of younger patients diagnosed with
cancer every year in India [95]. The presence of a com-
mon genetic susceptibility factor(s) amongst Saudis is
unknown. Interestingly, no significant associations of
BRCA1 and BRCA2 mutations or SNP have been found
in Saudi breast cancer cohorts [96,97]. However, there is
an ongoing study to elucidate this further at CEGMR
using high throughput technologies including Ion Torrent
whole genome sequencing. In addition, our exome
sequencing efforts of familial breast cancer cases have yet
to reveal a common gene or mutation in the samples so
far analysed [98]. Interestingly, every family sequenced
thus far has a different underlying putative defective gene
(s) precluding our ability to provide supporting evidence
for the hypothesis that suggests the presence of a consan-
guinity-driven common genetic haplotype associated with
increased susceptibility to breast cancer [98]. A more
defined role for a “cancer susceptibility genome” will
be determined following the conclusion of the SHGP
project [99].
Epigenetics could therefore play a major role in the
shift towards a younger age of onset. Life-style changes
such as sleep and shift work patterns, diet and exercise
can affect the genome in several ways and need to be
considered. The circadian rhythm, mediated through an
intricate network of transcriptional and post-translational
mediators is necessary for maintaining a healthy homeos-
tasis [100-102]. When the circadian rhythm is disrupted
through sleep deprivation, global changes in gene expres-
sion can occur altering cellular behaviour. Methylation is
a key mechanism for altering gene expression in response
to sleep deprivation, such as what happens to the brain
function [103]. The pleiotropic melatonin is the main
sensor for light and it has cancer-protective effects
through several mechanisms, including regulating estro-
gen pathway [104]. Interestingly, we have identified fre-
quent hypermethylation of the melatonin receptor,
MTNR1B, in a fraction of our cohort of breast cancer
cases (35%) with significant association with histological
grade I [105]. Such a result is intriguing and could impli-
cate the epigenetic deregulation of key components of
the circadian clock, which in turn, could potentiate can-
cer at an early age [100,101].
Sleep deprivation is not the only suspect behind the age
shift observed. Aberrant metabolism is also likely to play
a role. The incidence rates of the metabolic syndrome
(obesity, high blood pressure, elevated fasting glucose
Figure 5 Most common cancer types in the period 1998-2007 for children between 0-14 years from the GCC states [68]. Leukaemia, brain
cancer, Hodgkin’s diseases, and NHL were the most common malignancies in both genders.
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levels, elevated cholesterol levels) in Saudi Arabia are
reported to be among the highest in the world [106].
There is also emerging evidence of metabolic syndromes
contributing to the increasing rates and age shift of cancer
in Saudi Arabia. Our genome-wide methylation analysis of
breast cancer has identified a role for the KLOTHO-
FGF19-FGF23-FGFR4 signaling axis. FGF19 expression is
elevated and is associated with a significantly shorter life
expectancy of breast cancer patients of Saudi and Libyan
descent [107]. The upregulation of FGF19 expression is
coupled with high FGF23 and FGFR4 expression and fre-
quent methylation of KLOTHO in the same cohort
(Unpublished data). While a role for FGFR4 has been pre-
viously shown [108,109], implicating the metabolic hor-
mones FGF19, FGF23 and KLOTHO in cancer is equally
intriguing; the emerging question being if dysregulation of
these genes may be a direct cause of carcinogenesis or
more generally a symptom of metabolic health, which in
itself predisposes to cancer at a significantly younger age?
More work is warranted to shed light on the role of this
metabolic axis in cancer because of its potential as an
actionable target for treatment [110,111].
Other genes are inactivated by promoter hypermethyla-
tion. In colorectal cancer from Saudi Arabia, the methyla-
tion of the polycomb gene targets in the absence of CpG
island methylator phenotype (CIMP) is a predictor of
favourable prognosis [112]. Interestingly, we have identi-
fied a group of older patients with no detectable methyla-
tion in the genes analysed and yet displayed aggressive
tumours that led to a significantly lower disease-specific
survival rates [112]. The most frequent methylation event
detected in breast cancer from Saudi cases is at the
RASSF1A promoter, an event that is a potential predictor
of poor prognosis [113]. However, the methylation fre-
quency of other genes analysed in that study was lower
than reported elsewhere, especially in the case of Estrogen
Receptor-1 (ESR1) and Cadherin-1 (CDH1) methylation
[113]. This could be attributed to the relatively early age of
onset for the patients analysed, or to the presence of regio-
nal and ethnic-specific differences in gene regulation in
breast cancer. BRCA1 methylation in blood from breast
cancer patients could provide a potential mechanism for
cancer susceptibility in the Saudi population and offer a
promising tool for the detection of cancer predisposition
[114]. Amplification of TNRC9, a common event in breast
cancer from the MENA region, can directly result in the
epigenetic silencing of BRCA1 expression [115]. Inciden-
tally, SNPs in the TNRC9 locus have been shown to be
significantly associated with breast cancer [116].
Other epigenetic lesions underlying cancer in Saudi
Arabia could exist. Differential expression of miRNAs
including hsa-mir-146a2, hsa-mir-196a2 and hsa-mir-499
are detected in peripheral blood of breast cancer patients
[117]. Furthermore, polymorphisms identified in those
miRNAs have been found to be significantly associated
with breast cancer susceptibility [117]. A similar effect is
observed in risk modification for prostate cancer in
northern Indian populations [118]. Polymorphisms in
hsa-mir-196a has been shown to be associated with
increased risk for nasopharyngeal carcinoma in Chinese
patients [119], and with increased risk for non-small cell
lung carcinoma in the Korean population [120]. Conver-
sely, these genetic variants do not seem to influence
breast cancer risk or age of onset in German or Italian
populations [121].
V. Pharmacogenomics and personalized medicine
Pharmacogenomics (PGx) is the study of the role of
genetic polymorphisms in drug response [122,123]. PGx
is a rapidly evolving field in particular due to the rapid
advances in genotyping platforms and NGS technologies
to scan the genome at increasing levels of resolution
[124]. The interface of PGx and complex diseases
including various types of cancers, understanding and
managing serious adverse drug reactions (SADRs), and
public health pharmacogenetics, are the major areas of
investigation at CEGMR and elsewhere [124,125].
The potential opportunities emerging from PGx
include, but not limited to, the prediction of persona-
lized response to drugs, tailor-made prescriptions, redu-
cing adverse drug reactions (ADRs), increasing the
efficacy and reducing the toxicity of drugs, developing
more robust and safer vaccines, monitoring and screen-
ing of specific diseases, as well as advancing research
and development of novel drugs [122]. Pharmacoge-
netics (PGt) is the study of single genes that have signif-
icant influence on clinically actionable drugs [126].
In the past two decades, several drugs were primarily
withdrawn from the USA market due to ADRs
[125,127,128]. The ADRs are broadly categorized into
Type A and B reactions [127]. Type A reactions are pre-
dictable, dose-dependent and constitute about 80% of
ADRs [125,127]. The hypotension with anti-hypertensive
treatment and incidences of bleeding in patients treated
with Warfarin are some of the examples of Type A
ADRs [125,127]. However, Type B reactions are termed
as “idiosyncratic” or random ADRs observed mostly in
genetically susceptible individuals [127]. Moreover, Type
B reactions may potentially lead to SADRs that require
either temporary or prolonged hospitalization and in
some instances permanent disability or are even fatal
[125,129]. Deciphering the genetic variations in popula-
tions [130], associated with Type B reactions using PGx
strategies, could markedly reduce the healthcare bud-
gets, promote drug discovery and the development of
reliable and safer drugs [125,129].
The Cytochrome P450 (CYP450) super-family consists
of functionally diverse groups of drug detoxifying
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enzymes encoded by 57 genes and 5 pseudo genes, iden-
tified thus far, in the human genome [131,132]. The
CYP450 enzymes are chiefly expressed in liver and facil-
itate the metabolism of drugs, xenobiotics, toxic pollu-
tants, steroids, vitamin D, cholesterol metabolism and
bile synthesis, retinoic acid, arachidonic acid and eicosa-
noids [132,133] by conjugating with functional groups
and eventually removal from the body [132,134,135].
Members of the CYP450 super-family like CYP1, CYP2,
and CYP3 are essential for the phase I metabolism of
about 90% of all clinically applicable drugs [134-136].
The personalized variations in the expression of chief
detoxifying CYP450 enzyme systems in humans, such as
CYP1A2, CYP2C, CYP2D6, CYP2E1, CYP3A4 and
CYP3A5, can influence the metabolism of a clinically
relevant drug and the ADRs associated with its standard
doses [124,135,136]. An array of factors such as the
genetic polymorphisms, poor diet, endocrine dysregula-
tion, epigenetic changes, acute and chronic liver diseases
can critically influence the personalized variation in the
expression of CYP450 system [135,137]. Besides, the
CYP450 clinical phenotypes are classified based on indi-
viduals’ ability to metabolize a particular drug as ultra-
rapid metabolizers (UMs), Extensive Metabolizers
(EMs), Intermediate Metabolizers (IMs) and poor meta-
bolizers (PMs) [138,139]. The PMs have two non-func-
tional alleles that decrease the expression of a particular
CYP450 enzyme [136]; IMs have one functional allele
and one heterozygous null allele for a CYP450 enzyme
[136]. EMs have two functional homozygous alleles and
may require higher concentrations of a therapeutic drug
compared with IMs and PMs [136]. UMs have two or
more copies of a functional CYP450 gene and metabo-
lize the drug substrates rapidly and always require
higher concentrations of drugs to achieve good thera-
peutic outcomes [136].
Genetic polymorphisms of CYP450 superfamily of
genes greatly influence the efficacy, safety and the clini-
cal outcome of a drug treatment [136]. CYP2D6 is one
of most important CYP450 enzyme required for the
metabolism of more than 30% of therapeutically relevant
drugs, including antidepressants and antipsychotics
[138,139]. It is polymorphically expressed, and found to
be absent in 1- 2% of Asians, 6 - 10% of Caucasians
[139] and are classified as PMs [138,139]. Over 25% of
Ethiopians and 2% of Caucasians are classified as
CYP2D6 UMs [138,140]. In general, PMs of drugs have
an increased risk of developing ADRs when compared
to UMs and EMs. For example, codeine, a pro-drug, is
converted to morphine by CYP2D6 enzyme to exert its
analgesic properties [140]. Therefore, the efficacy of
codeine was significantly reduced in individuals with
CYP2D6 PMs [140]. On the other hand, the efficacy of
codeine was markedly increased in CYP2D6 IMs and
CYP2D6 UMs leading to drug toxicity in some indivi-
duals [140].
CYP2C subfamily of enzymes metabolizes about 20% of
clinically relevant drugs including non-steroidal anti-
inflammatory drugs (NSAIDs), oral anticoagulants and
oral anti-diabetic agents such as tolbutamide, glibencla-
mide, glimepiride and glipizide [141-143]. To date, more
than 57 alleles of CYP2C9 have been reported [144]
amongst which CYP2C9*2 and CYP2C9*3 alleles are the
most prevalent in Caucasian as well as Asian populations
and individuals carrying these polymorphisms exhibit
reduced CYP2C9 activity [141]. An association was estab-
lished between reduced expression of CYP2C9 and higher
risk of bleeding episodes and upper-gastrointestinal (GI)
bleeding in Warfarin-treated patients [136,145]. The alleles
of CYP2C9 namely, CYP2C9*2 and CYP2C9*3 are respon-
sible for reduced CYP2C9 enzyme activity leading to
increased anti-coagulation [136]. These patients should be
administered with lower dose of Warfarin to attain effec-
tive anti-coagulation, and diminish the possibility of bleed-
ing episodes [136,145,146].
In Oman, the frequencies for CYP2C9*2 and CYP2C9*3
alleles were shown as 7.4% and 2.9% respectively
[147,148]. In Egypt, the allelic frequencies of CYP2C9*2
and CYP2C9*3 alleles were estimated as 12% and 6%
respectively [149]. In Lebanon, the allele frequencies for
these two alleles were found to be 11.2% and 9.6%, respec-
tively [148,150]. The frequencies of CYP2C9*2 and
CYP2C9*3 alleles among Saudis in Al-Ahsa were about
13.4% and 2.3%, respectively [148]. In Riyadh, the frequen-
cies for CYP2C9*2 and CYP2C9*3 alleles were reported to
be 11.7% and 9.7% respectively [143]. The analysis of com-
mon genetic variants of the CYP2C9 subfamily in type 2
Diabetes mellitus (T2DM) patients in Jeddah showed that
the allele frequencies of CYP2C9*2 and CYP2C9*3 were
25% and 9.3%, respectively (personal communication,
Nehad Abdulqader Shaer and Ashraf Dallol). It was
recently shown that the incidence of CYP2C9 polymorph-
isms in Saudi population was comparable to Caucasians;
however, it was higher than Africans and Asians [151].
Saudi patients with CYP2C9*2 and CYP2C*3 alleles had
more adverse bleeding episodes and require 40%
less Warfarin dose to cause effective anti-coagulation
(Fig. 6) [151].
In December 2004, the United States food and drug
administration (FDA) approved the drug metabolizing
enzyme (DME) genotyping system from Roche named as
AmpliChipTMCYP450 array [152]. The AmpliChip P450
array is used in Affymetrix GeneChip microarray instru-
mentation system to identify a patient’s CYP2D6 and
CYP2C19 genotypes from genomic DNA isolated from
whole blood sample [152]. Based on the CYP450 genetic
test results, clinical evaluation and other lab tests as a
reference, the clinician designs personalized treatment
Abu-Elmagd et al. BMC Medical Genomics 2015, 8(Suppl 1):S3
http://www.biomedcentral.com/1755-8794/8/S1/S3
Page 10 of 17
options for patients to minimize the risk of ADRs and sub-
optimal dose response [152]. It was estimated that about
25% of all prescribed drugs in the USA contain PGx label-
ling [136,153], for example, the anti-coagulant Warfarin
with PGx indications of CYP2C9 genotype specific dosing
[136,154]. The FDA has published a table of PGx biomar-
kers in drug labelling of about 135 therapeutically relevant
drugs in the market [26,155].
Though the advancing technologies in genomics and
bioinformatics rapidly steer PGx towards personalized
therapy for patients in clinics, PGx tests are currently
limited to evaluate the safety and therapeutic efficacy of
drugs for thromboembolic complications associated with
atrial fibrillation and/or cardiac valve replacement,
human immunodeficiency virus, chronic myeloid leukae-
mia and gastrointestinal stromal tumours, ALL, colon,
breast and lung cancers [156].
At present, the key challenges of personalized medi-
cine include; achieving the goal of $1000 genome [157],
increasing the speed of genome or exome sequencing by
yet to be developed technologies [156], and making
these platforms user friendly. Moreover, establishing
dynamic PGx tools and databases [158-160], training
physicians to apply PGx results to formulate preventive
and personalized healthcare [161], and establishing
privacy rules will be required to further the translational
science [122,156]. At CEGMR, we are currently in the
process of establishing custom-built PGx tools and data-
bases as well as evaluating the PGx and toxicogenomics
of several drugs used for the treatment of diseases
afflicting Saudi population. Last, but perhaps most
important, will be to, establish proper allele frequencies
in populations from Saudi regions and others from
across the globe [123,156].
Discussion and summary
All of the investments in equipment in genomics infra-
structure, and informatics at CEGMR aid in generating
fundamental knowledge to facilitate effective decision
making for individuals and families. Our primary objective
is to generate the highest quality genomic data from
patients and relevant family and population controls to
enable opportunity for point-of-care, as well as iterative
decision making based on the comparative medical data
available. The advantage in the Saudi system is centralized
medical care and shared experiences in families, which
will also enable genome-based discoveries and treatments
among families, physicians, and researchers [162].
We also recognize the importance of thoughtful delibera-
tion on issues of societal awareness about consanguinity,
Figure 6 (A) Pie-chart represents the CYP2C9*2 and (B) CYP2C9*3 polymorphisms observed in some of the Middle Eastern countries. (C) The
percentage of CYP2C9*2 and CYP2C9*3 polymorphisms identified in Oman, Egypt, Lebanon, as well as in Al-Ahsa, Riyadh and Jeddah regions of
the KSA. The incidence of CYP2C9 polymorphisms in Saudi population was similar to Caucasians; but, it was more than Asians and Africans [169]
and adverse bleeding episodes are not uncommon in Saudi patients with CYP2C9*2 and CYP2C*3 alleles and may require 40% less Warfarin
dose to induce effective anti-coagulation [169].
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infertility, and stigma associated with some genetic disor-
ders and malformations. Therefore, the authority has
launched several education and outreach programs in hos-
pitals and schools [163]. CEGMR will continue to launch
proactive communication plans with stakeholders such as
government, media, children with disabilities, charitable
associations, and other society representatives. Coupled
with research, will also be newer ethical consenting pro-
cesses that are particularly conscience of the vast array of
genetic findings (and their implications) that arise from
genome scanning [164]. Much of the data will be amenable
to confidentiality, protection and control using an infor-
matics-based approach [165,166]. However, there remains
an urgent need in Saudi Arabia for up to date policies that
comply with international standards, which implement
strict control and protection of privacy and public release
of bio-specimens and data [166-168]. CEGMR will also
continue to develop and implement new algorithms and
databases enabling iterative dynamic interpretations of data
in personalized health decision making [169-171].
Other considerations relevant to translational medicine
in the Saudi system include making reproductive health
and ART more accessible and affordable for the average
Saudi citizen so this approach can further ease the current
staggering impact congenital malformations and genetic
disease are having on the health care system [41]. We
believe that there is a need for a strategic plan to recom-
mend the PGD for patients with hereditary genetic disor-
ders and receiving IVF services in the Kingdom. There
also needs to be proactive and clear policies on the use of
the human Embryonic Stem Cells (hESCs) and these
should be easily accessed by all who are interested in the
human stem cells research.
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